Exelixis, Inc. today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis ...

One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in ...

Advanced AI technology delivers instant, accurate property comparables to automate due diligence for real estate ...

A Type B meeting between the FDA and Plus Therapeutics offered clarity and direction for the next steps in development of ...

Any task that tests your mental muscles is a step in the right direction when improving your problem-solving skills. While ...

Learn about the bundle of rights in real estate—a set of key ownership privileges including possession, control, exclusion, ...

Threat actors are systematically hunting for misconfigured proxy servers that could provide access to commercial large ...

Security teams have always known that insecure direct object references (IDORs) and broken authorization vulnerabilities exist in their codebases. Ask any ...

Proposals for presentations at the Rocky Mountain Advanced Computing Consortium’s annual High Performance Computing Symposium ...

Revolution Medicines shows RAS drug optimism with phase 3 catalysts, early-stage valuation, buyout chatter, and competition ...

A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an ...

In the third part of her conversation with PharmExec, Trialynx founder and CEO Angela Schwab discusses the causes and ...